Latest Research And Development News

Page 40 of 82
Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.
Ada Torres
Ada Torres
29 Aug 2025
Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.
Ada Torres
Ada Torres
29 Aug 2025
PARKD Limited reported a remarkable 218% increase in revenue to $11.83 million for FY25, driven by key construction projects and new licensing agreements. The company narrowed its loss by 74%, signaling progress in commercialising its modular construction technology.
Victor Sage
Victor Sage
29 Aug 2025
Volt Group Limited reported a 24% revenue decline and a net loss of $271,854 for the half year ended June 2025, primarily due to timing delays in Wescone orders and iron ore sector shutdowns. Despite this, the company advances its innovative ATEN waste heat to power technology and expands its EcoQuip solar light tower fleet, while initiating a 12-month on-market share buy-back.
Maxwell Dee
Maxwell Dee
29 Aug 2025
PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.
Victor Sage
Victor Sage
29 Aug 2025
Island Pharmaceuticals reported a $3.92 million loss for FY2025 despite an 86% increase in income, with no dividends declared.
Ada Torres
Ada Torres
29 Aug 2025
TrivarX Limited reported a reduced net loss of $943K for FY25 alongside a $3.68 million equity raise, yet flagged material uncertainty over its ability to continue as a going concern.
Ada Torres
Ada Torres
29 Aug 2025
Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.
Ada Torres
Ada Torres
29 Aug 2025
Austal Limited has reported a remarkable 24% revenue increase and a 503% surge in net profit for FY2025, yet has chosen not to declare any dividends for the year.
Victor Sage
Victor Sage
29 Aug 2025
Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.
Ada Torres
Ada Torres
28 Aug 2025
Sparc Technologies reported a narrower FY25 loss alongside progress in green hydrogen and graphene additive projects, supported by government grants and a successful capital raise.
Victor Sage
Victor Sage
28 Aug 2025